2906 related articles for article (PubMed ID: 28012440)
1. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
2. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
3. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
4. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
5. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
6. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
7. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
Roh JL; Jang H; Kim EH; Shin D
Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
[TBL] [Abstract][Full Text] [Related]
8. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
9. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
Kim EH; Shin D; Lee J; Jung AR; Roh JL
Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
[TBL] [Abstract][Full Text] [Related]
10. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant Head and Neck Cancer Cells to Ferroptosis.
Lee J; You JH; Shin D; Roh JL
Theranostics; 2020; 10(17):7775-7786. PubMed ID: 32685019
[No Abstract] [Full Text] [Related]
12. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
13. Activation of p62-Keap1-Nrf2 Pathway Protects 6-Hydroxydopamine-Induced Ferroptosis in Dopaminergic Cells.
Sun Y; He L; Wang T; Hua W; Qin H; Wang J; Wang L; Gu W; Li T; Li N; Liu X; Chen F; Tang L
Mol Neurobiol; 2020 Nov; 57(11):4628-4641. PubMed ID: 32770451
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic resistance of head and neck squamous cell carcinoma is mediated by EpCAM induction driven by IL-6/p62 associated Nrf2-antioxidant pathway activation.
Noman ASM; Parag RR; Rashid MI; Islam S; Rahman MZ; Chowdhury AA; Sultana A; Jerin C; Siddiqua A; Rahman L; Nayeem J; Akther S; Baidya S; Shil RK; Rahman M; Shirin A; Mahmud R; Hossain SMI; Sumi SA; Chowdhury A; Basher SB; Hasan A; Bithy S; Aklima J; Chowdhury N; Hasan MN; Banu T; Chowdhury S; Hossain MM; Yeger H; Farhat WA; Islam SS
Cell Death Dis; 2020 Aug; 11(8):663. PubMed ID: 32814771
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
[TBL] [Abstract][Full Text] [Related]
16. Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling.
Fu D; Wang C; Yu L; Yu R
Cell Mol Biol Lett; 2021 Jun; 26(1):26. PubMed ID: 34098867
[TBL] [Abstract][Full Text] [Related]
17. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
18. Ethanol extract of Eclipta prostrata induces multiple myeloma ferroptosis via Keap1/Nrf2/HO-1 axis.
Li W; Yin X; Fu H; Liu J; Weng Z; Mao Q; Zhu L; Fang L; Zhang Z; Ding B; Tong H
Phytomedicine; 2024 Jun; 128():155401. PubMed ID: 38507850
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62-Keap1-NRF2 pathway.
Li Y; Xu B; Ren X; Wang L; Xu Y; Zhao Y; Yang C; Yuan C; Li H; Tong X; Wang Y; Du J
Cell Mol Biol Lett; 2022 Sep; 27(1):81. PubMed ID: 36180832
[TBL] [Abstract][Full Text] [Related]
20. The discovery and characterization of K-563, a novel inhibitor of the Keap1/Nrf2 pathway produced by Streptomyces sp.
Hori R; Yamaguchi K; Sato H; Watanabe M; Tsutsumi K; Iwamoto S; Abe M; Onodera H; Nakamura S; Nakai R
Cancer Med; 2019 Mar; 8(3):1157-1168. PubMed ID: 30735010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]